We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Urine Protein Test Can Predict Dementia Risk

By LabMedica International staff writers
Posted on 26 Sep 2025

Dementia remains one of the most pressing health challenges worldwide, with age as the greatest risk factor. More...

Increasingly, research suggests that diseases in other organs, such as the kidneys, may play a role in its development. Identifying markers that link kidney health to brain function could provide an early warning for cognitive decline. Now, a new study has shown that a common protein found in urine may indicate an increased risk of developing dementia later in life.

The study, conducted by researchers at Karolinska Institutet (Stockholm, Sweden), investigated the role of albuminuria—an abnormal condition where the protein albumin leaks into urine. Normally, healthy kidneys filter waste products while keeping essential proteins like albumin in the blood. Elevated albumin levels indicate kidney damage and, according to this research, may also reflect vascular changes that predispose individuals to dementia.

Researchers followed 130,000 adults aged over 65 in Stockholm who were free of dementia at baseline. Over four years, 7 percent developed dementia. After adjusting for kidney function and other health factors, results showed that those with moderate albuminuria (30–299 mg/g) had a 25 percent higher risk of dementia, while those with high levels (≥300 mg/g) had a 37 percent greater risk compared to participants with normal albumin levels.

The association was particularly strong for vascular dementia, often caused by stroke, high blood pressure, diabetes, or vascular disease, and for mixed dementia, which combines vascular and Alzheimer’s features. The findings, published in the Journal of Internal Medicine, highlight how kidney dysfunction may mirror damage in the brain’s small vessels, influencing the blood-brain barrier and increasing the risk of harmful protein buildup linked to dementia.

The study underscores the potential of routine screening for albuminuria in older adults and in patients with conditions like hypertension, diabetes, cardiovascular disease, or kidney disease. Detecting the condition early could allow for preventive interventions to reduce or delay dementia onset. Researchers suggest integrating this simple urine test into dementia risk assessments to improve outcomes and reduce disease burden.

"These results underscore the importance of routine screening for albuminuria as part of early dementia risk assessment, especially in patients with high blood pressure, diabetes, cardiovascular disease, or kidney disease,” said Hong Xu, assistant professor at Karolinska Institutet and last author of the study. “Early detection of albuminuria could potentially delay or prevent the onset of dementia."

Related Links:
Karolinska Institutet


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.